Biomarkers are revolutionizing personalized medicine by guiding treatment decisions. Predictive biomarkers help in determining which patients are likely to benefit from a particular treatment. For example, the presence of EGFR mutations in non-small cell lung cancer can predict responsiveness to EGFR inhibitors. Similarly, BRCA mutations in breast and ovarian cancers can guide the use of PARP inhibitors.